Current opinion in ophthalmology (Curr Opin Ophthalmol)

Publisher: Lippincott, Williams & Wilkins

Journal description

Topics Covered: Cataract Surgery and Lens Implantation; Glaucoma; Retina and Vitreous Disorders; Corneal and External Disorders and Refractive Surgery; Strabismus; Oculoplastic and Orbital Surgery; Neuro-ophthalmology; Ocular Manifestations of Systemic Disease.

Current impact factor: 2.50

Impact Factor Rankings

2015 Impact Factor Available summer 2016
2014 Impact Factor 2.5
2013 Impact Factor 2.638
2012 Impact Factor 2.557
2011 Impact Factor 2.647
2010 Impact Factor 2.429
2009 Impact Factor 2.49
2008 Impact Factor 2.958

Impact factor over time

Impact factor

Additional details

5-year impact 2.69
Cited half-life 6.80
Immediacy index 0.42
Eigenfactor 0.01
Article influence 0.89
Website Current Opinion in Ophthalmology website
Other titles Current opinion in ophthalmology (Online), Current opinion in ophthalmology
ISSN 1531-7021
OCLC 36903873
Material type Document, Periodical, Internet resource
Document type Internet Resource, Computer File, Journal / Magazine / Newspaper

Publisher details

Lippincott, Williams & Wilkins

  • Pre-print
    • Author can archive a pre-print version
  • Post-print
    • Author cannot archive a post-print version
  • Restrictions
    • 12 months embargo
  • Conditions
    • Some journals have separate policies, please check with each journal directly
    • Pre-print must be removed upon acceptance for publication
    • Post-print may be deposited in personal website or institutional repository
    • Publisher's version/PDF cannot be used
    • Must include statement that it is not the final published version
    • Published source must be acknowledged with full citation
    • Set statement to accompany deposit
    • Must link to publisher version
    • NIH authors will have their accepted manuscripts transmitted to PubMed Central on their behalf after a 12 months embargo (see policy for details)
    • Wellcome Trust and HHMI authors will have their accepted manuscripts transmitted to PubMed Central on their behalf after a 6 months embargo (see policy for details)
    • Publisher last reviewed on 19/03/2015
  • Classification
    ‚Äč yellow

Publications in this journal

  • [Show abstract] [Hide abstract]
    ABSTRACT: Purpose of review: Cataract surgery in high myopes is challenging. Using third-generation intraocular lens (IOL) formulas, without adjustments, hyperopic refractive outcomes are common. We discuss these issues, focusing on the various lens formulas and transformations that have improved postoperative accuracy. Recent findings: Axial length measurement error has been largely overcome by the use of optical interferometry. Despite this, consistent hyperopic errors are still reported. We reviewed the postoperative refraction results compared with the predicted refractions using: standard formulas (Holladay 1, SRK/T, Hoffer Q, and Haigis) with manufacturers' optical lens constants, the User Group for Laser Interference Biometry (ULIB) constants, manufacturers' constants with axial length adjustment method, and fourth-generation IOL formulas (Barrett Universal II, Holladay 2, and Olsen). Summary: Improved predictive results is obtained with the Barrett Universal II (software constants), Haigis (ULIB), SRK/T, Holladay 2 (software constants), and Olsen (software constants) formulas in eyes with axial lengths greater than 26.0 mm and IOL powers greater than 6.0 D. In eyes with axial lengths greater than 26.0 mm and IOL less than 6.0 D, the Barrett Universal II formula (software constants) and the Haigis (axial length adjusted) and Holladay 1 formulas (axial length-adjusted) should be used.
    Current opinion in ophthalmology 11/2015; DOI:10.1097/ICU.0000000000000217
  • [Show abstract] [Hide abstract]
    ABSTRACT: Purpose of review: The review evaluates the past 18-month literature related to cost-effectiveness of treating ocular hypertension (OHT) and give an opinion of the state of research. Recent findings: Three studies question the value of intensive monitoring in OHT and glaucoma. One study suggests that implementing Ocular Hypertension Treatment Study - European Glaucoma Prevention Study risk prediction in every day practice overestimates the risk of open-angle glaucoma. While two models suggest that treating all intraocular pressures above 21 mmHg would be cost-saving (but disagree on the impact of this strategy on conversion to glaucoma), another study in turn suggests than we could safely reduce medications in almost half of the patients. Two studies suggest that effective early treatment could decrease follow-up costs in OHT and one modeling study suggests that using laser in preference to medication would be cost effective in glaucoma. Summary: The results of this time-limited review are confusing as they challenge many current beliefs to continue to do more than what we are currently doing. We have a huge gap in understating whether we are currently doing the 'right' things in our every day practices.
    Current opinion in ophthalmology 11/2015; DOI:10.1097/ICU.0000000000000233
  • [Show abstract] [Hide abstract]
    ABSTRACT: Purpose of review: Optical coherence tomography (OCT) aids in the diagnosis and long-term monitoring of various ocular diseases, including glaucoma. Initially, the retinal nerve fiber layer was the only OCT structural parameter used in glaucoma. Subsequent research has resulted in more retinal and optic nerve head parameters. In addition, OCT is being investigated for its ability to assess ocular hemodynamics. This review summarizes these spectral domain-optical coherence tomography (SDOCT) parameters in the context of glaucoma. Recent findings: Several new SDOCT retinal nerve fiber layer, optic nerve head, and macular parameters with good glaucoma diagnostic ability have been added to existing ones recently. The combination of SDOCT and Doppler or angiography has also resulted in hemodynamic parameters that may prove to be useful in the functional assessment in glaucoma. Summary: OCT technology is advancing not only as a tool for structural assessment, but also as a multimodality tool to assess both structure and function to enhance our understanding of glaucoma, and ultimately clinical decisions.
    Current opinion in ophthalmology 11/2015; DOI:10.1097/ICU.0000000000000231
  • [Show abstract] [Hide abstract]
    ABSTRACT: Purpose of review: To discuss the increasing utilization of cataract extraction in the management of glaucoma and to highlight advances in surgical care that can promote synergistic treatment of these comorbid conditions. Recent findings: Recent years have demonstrated significant advances in the management of glaucoma through the use of novel microinvasive glaucoma devices. Furthermore, an increased understanding of the role of cataract surgery in the treatment of various glaucomas warrants review. Nevertheless, cataract surgery in the glaucoma patient warrants specific preoperative, intraoperative, and postoperative planning to optimize visual function and quality of life while mitigating potential risk factors for adverse events. Summary: Although the challenges of performing cataract extraction on glaucoma patients exist, the potential benefit to these patients is substantial. With attention to pre- and perioperative surgical planning and intraoperative technique, as well as with awareness and potential utilization of novel devices and treatment strategies, cataract extraction offers a unique platform for anatomical and functional improvement in this increasingly common cohort of patients.
    Current opinion in ophthalmology 11/2015; DOI:10.1097/ICU.0000000000000224
  • [Show abstract] [Hide abstract]
    ABSTRACT: Purpose of review: To review the relationship between cognitive function and cataract surgery, as it is rarely addressed, and yet is becoming increasingly important as the number of elderly people in the world continues to rise. Recent findings: From US Census and international data, it is expected that the predicted proportion of people over 65 years of age in a number of countries will increase drastically over a half century. Therefore, the percentage of patients with cataracts and cognitive impairment, which are both age-related diseases, will be expected to rise as well. Although there are many papers reporting on the association between visual impairments and cognitive impairments, there is a relative dearth of research supporting the hypothesis that cataract surgery can improve cognitive function in patients with cognitive impairment. This reflects some inherent problems with most cognitive tests, which include both vision-dependent and vision-independent items. There may also be an element of learning from repeated cognitive tests, which may falsely elevate test scores. Summary: There is an increase in reports supporting the hypothesis that cataract surgery can improve cognition; however, there is still insufficient evidence for cognitive improvement after cataract surgery. As this is a growing area of research, we expect more studies to shed light on this relationship.
    Current opinion in ophthalmology 11/2015; DOI:10.1097/ICU.0000000000000226
  • [Show abstract] [Hide abstract]
    ABSTRACT: Purpose of review: To provide a summary of the mechanisms that may cause dry eye after cataract surgery and discuss available and upcoming treatment modalities. Recent findings: Development or worsening of dry eye symptoms after cataract surgery is multifactorial with corneal nerve transection, inflammation, goblet cell loss, and meibomian gland dysfunction commonly cited as underlying disorders. With increasing awareness of the prevalence of dry eye disease, current surgical techniques are being analyzed for their contribution to the issue. Although many classic interventions, such as artificial tears and anti-inflammatory drops, remain first-line treatment options, they may not adequately address abnormalities of the tear film. The trend has been to create new drugs and technologies that target meibomian gland deficiencies and restore goblet cell numbers. Summary: Therapy for postoperative dry eye symptoms should be determined based on symptom severity and which underlying cause is most prominent at a given time. Patients with high-level risk factors for dry eye should be evaluated preoperatively to determine whether they have preexisting dry eye disease or if they are susceptible to developing disease after surgery.
    Current opinion in ophthalmology 11/2015; DOI:10.1097/ICU.0000000000000227
  • [Show abstract] [Hide abstract]
    ABSTRACT: Purpose of review: This article raises awareness about the cost-effectiveness and carbon footprint of various cataract surgery techniques, comparing their relative carbon emissions and expenses: manual small-incision cataract surgery (MSICS), phacoemulsification, and femtosecond laser-assisted cataract surgery. Recent findings: As the most commonly performed surgical procedure worldwide, cataract surgery contributes significantly to global climate change. The carbon footprint of a single phacoemulsification cataract surgery is estimated to be comparable to that of a typical person's life for 1 week. Phacoemulsification has been estimated to be between 1.4 and 4.7 times more expensive than MSICS; however, given the lower degree of postoperative astigmatism and other complications, phacoemulsification may still be preferable to MSICS in relatively resource-rich settings requiring high levels of visual function. Limited data are currently available regarding the environmental and financial impact of femtosecond laser-assisted cataract surgery; however, in its current form, it appears to be the least cost-effective option. Summary: Cataract surgery has a high value to patients. The relative environmental impact and cost of different types of cataract surgery should be considered as this treatment becomes even more broadly available globally and as new technologies are developed and implemented.
    Current opinion in ophthalmology 11/2015; DOI:10.1097/ICU.0000000000000228
  • [Show abstract] [Hide abstract]
    ABSTRACT: Purpose of review: The purpose of the present study is a systematic review of previous studies on choosing the best incision site for the correction of astigmatism in cataract surgery and assessing the amount of surgically induced astigmatism (SIA) with each approach. Recent findings: Regardless of astigmatism axis, studies show that using an on-axis incision is associated with favorable results for 0.5-1.0 diopter (D) of astigmatism. In cases with more than 1.0 D astigmatism, paired on-axis incisions can be appreciably efficient in astigmatism correction and cause at least 1.5 D SIA. Considering the amount of SIA, a temporal incision is the best approach when the patient has minimal amounts of corneal astigmatism preoperatively. At higher levels of astigmatism, if no other astigmatism correction method is used simultaneously, the temporal incision is used less frequently; however, since it is associated with the least SIA, it is still the choice site when another correction method is used. Summary: The temporal incisions in cataract surgery are associated with little SIA and are appropriate choices for mild preoperative astigmatism. At higher levels of preoperative astigmatism, superior incisions are associated with better results when combined methods are not applied.
    Current opinion in ophthalmology 11/2015; DOI:10.1097/ICU.0000000000000223
  • [Show abstract] [Hide abstract]
    ABSTRACT: Purpose of review: This article reviews current concepts in intraocular lens alignment strategies to maximize intraocular lens (IOL) positioning. Recent findings: A variety of strategies has been developed to maximize toric IOL position, including preoperative calculators to determine the appropriate IOL power and orientation, intraoperative alignment devices, and postoperative software to determine if IOL rotation would be beneficial for refractive outcomes. Summary: The combination of using multiple toric IOL calculators and intraoperative alignment devices has improved toric IOL outcomes. The relationship of the posterior corneal power and its effect on outcomes remains to be fully elucidated. Postoperative IOL rotation may be necessary even when the IOL is aligned as planned because of surgically induced astigmatism.
    Current opinion in ophthalmology 11/2015; DOI:10.1097/ICU.0000000000000225
  • [Show abstract] [Hide abstract]
    ABSTRACT: Purpose of review: Postoperative endophthalmitis is an ophthalmic surgeon's most feared complication, as it portends a high probability of visual loss. The purpose of this article is to review the literature on the subject of preoperative measures used for prevention of postoperative endophthalmitis and to determine the effectiveness of these measures. Recent findings: The present reviewed literature regarding topical prophylaxis of endophthalmitis in cataract surgery. Summary: There is strong evidence for the use of povidone-iodine preoperatively for prophylaxis of postoperative endophthalmitis in ocular surgery; the evidence for topical antibiotics is not as compelling.
    Current opinion in ophthalmology 11/2015; DOI:10.1097/ICU.0000000000000216

  • Current opinion in ophthalmology 11/2015; DOI:10.1097/ICU.0000000000000230
  • [Show abstract] [Hide abstract]
    ABSTRACT: Purpose of review: The purpose of this study is to discuss current controversies surrounding the proposed treatments for traumatic optic neuropathy (TON) and review recent evidence from the literature relating to these therapeutic options. Recent findings: No recent randomized controlled trials investigating surgical or medical interventions for TON exist. The current literature regarding treatment of TON consists mainly of small, mostly retrospective, observational studies. Treatment of TON with corticosteroids, surgical decompression of the optic canal or combinations of surgery and corticosteroids does not appear to offer improved visual outcomes compared with observation alone. Recent evidence suggests that there may be diminished functional reserve of the optic nerve following trauma. Novel neuroprotective therapies, such as erythropoietin, are currently under investigation in the treatment of TON. Summary: TON may lead to profound visual disability. Because of the absence of Class I evidence relating to treatment of TON, a lack of consensus exists among clinicians regarding the appropriate treatment for TON. Our review of the recent literature finds that there is still no reliable evidence that treatment of TON with corticosteroids, surgical optic canal decompression or both confers any benefit over observation alone, and yet these interventions incur an additional risk that may not warrant their routine use.
    Current opinion in ophthalmology 10/2015; 26(6):445-449. DOI:10.1097/ICU.0000000000000198
  • [Show abstract] [Hide abstract]
    ABSTRACT: Purpose of review: The purpose of this article is to review the current literature on Vogt-Koyanagi-Harada (VKH) disease, including current treatment options and new research directions. Recent findings: Recent publications on VKH disease show an increased focus on the immunogenetics and immune pathways associated with the development of VKH disease. There have also been advances in imaging modalities and techniques that may help to better elucidate the disease process in eyes with VKH disease. Summary: VKH disease is an autoimmune, multisystem inflammatory disorder, the cause of which is still incompletely understood. Continued research may elucidate the causes and triggers of immune dysregulation in this disease, and in doing so, identify novel therapeutic targets.
    Current opinion in ophthalmology 10/2015; 26(6):506-511. DOI:10.1097/ICU.0000000000000206
  • [Show abstract] [Hide abstract]
    ABSTRACT: Purpose of review: To discuss recent advances in potential treatments for Leber hereditary optic neuropathy (LHON), a typically visually devastating hereditary optic neuropathy caused by mutations in the mitochondrial genome. Recent findings: Idebenone has been proposed as a means of bypassing defective complex I activity and a free radical scavenger to prevent oxidative damage. EPI-743 may have more potency than idebenone, but no clinical trials have been performed. Gene therapy techniques have advanced significantly, including allotopic expression and nuclear transfer. Successful rescue of animal models of LHON with both of these therapies has been demonstrated. Introduction of exogenous DNA into the mitochondrial genome with mitochondrial targeting of viral vectors is another promising technique. Summary: There are currently no proven treatments for LHON. However, there are many promising novel treatment modalities that are currently being evaluated, with several clinical trials underway or in the planning stages. Supportive measures and genetic counseling remain of great importance for these patients.
    Current opinion in ophthalmology 10/2015; 26(6):450-457. DOI:10.1097/ICU.0000000000000212
  • [Show abstract] [Hide abstract]
    ABSTRACT: Purpose of review: Sarcoidosis is a multisystem inflammatory disease, characterized by the presence of noncaseating granulomas. Ocular inflammation is often the first manifestation of the disease, and uveitis can be the driving force for treatment. The goal of this review was to provide an update on the relationship between ocular and systemic disease, with a particular focus on cardiac sarcoidosis. Recent findings: Chest radiograph remains the best imaging tool for sarcoidosis, although newer modalities, such as whole-body PET scan, cardiac MRI, and chest computed tomography (CT), may provide additional valuable information in select populations. Ocular sarcoidosis is a marker for vascular endothelial dysfunction and increased arterial rigidity. Choroidal involvement is associated with an increased risk of cardiac disease requiring intervention. Cardiac disease continues to be underdiagnosed in patients with sarcoidosis, although it remains a leading cause of death. Summary: Sarcoidosis is a systemic disease, and ophthalmologists should continually assess patients for extraocular manifestations. Although no screening guidelines exist, baseline ECGs on asymptomatic patients might identify those at risk for adverse cardiac events. Patients with symptoms of cardiac disease, including palpitations, chest pain, and dyspnea, should have an evaluation by a cardiologist.
    Current opinion in ophthalmology 10/2015; 26(6):512-516. DOI:10.1097/ICU.0000000000000207
  • [Show abstract] [Hide abstract]
    ABSTRACT: Purpose of review: To review important eye movement disorders in multiple sclerosis (MS) and update the ophthalmologist on disease-modifying therapies in MS, from the perspective of expert neurologists. Recent findings: A large study confirmed that eye movement abnormalities in MS can be commonly identified by bedside examination. Identifying such ocular motility disturbances can assist in the diagnosis and prognosis for patients with MS. Articles published on such agents as oral teriflunomide and the biologics, natalizumab and alemtuzumab, have defined emerging roles of these treatments in the management of MS. Summary: Many patients with MS suffer from isolated or a combination of eye movement disorders. Understanding their ocular motility disturbance patterns can help diagnose MS and correlate with the progression of MS. Exciting advances in MS disease-modifying treatments have been developed. Patients have more options than ever before of injectable, infusion and oral therapies. The therapeutic efficacy in lowering relapse rates is counterbalanced by these drugs' side-effects.
    Current opinion in ophthalmology 09/2015; 26(6). DOI:10.1097/ICU.0000000000000211
  • [Show abstract] [Hide abstract]
    ABSTRACT: Purpose of review: The present review summarizes the body of literature concerning the medical and surgical treatment of thyroid eye disease (TED) from 1 January 2014 through 30 March 2015. Recent findings: Corticosteroids continue to be the primary medical therapy for TED. Recent research has offered insight into potential differences between oral corticosteroid and intravenous corticosteroid treatment regimens in terms of efficacy and side-effect profiles. Steroid-sparing medications, for example, rituximab and others, are an area of active study. There has been renewed interest in the role of radiation therapy as a nonmedical treatment for TED with some promising data. The use of balanced orbital decompression techniques have become popular, although the data regarding postoperative diplopia are mixed, and 'fat decompression' offers an alternative or an augmentation to bony decompression. Stereotactic image guidance is a useful adjunct to orbital decompression surgery. Summary: TED continues to be a difficult condition for the patient to cope with and for the clinician to treat, and recent research builds on the present foundation of knowledge and treatments, but unfortunately does not offer paradigm-shifting information at the present time.
    Current opinion in ophthalmology 09/2015; 26(6). DOI:10.1097/ICU.0000000000000203
  • [Show abstract] [Hide abstract]
    ABSTRACT: Purpose of review: Giant cell arteritis (GCA) remains a potentially blinding inflammatory vasculitis of the elderly. Because prolonged doses of corticosteroids remain the best established treatment, side-effects during treatment are common and potentially serious. This review addresses the challenges clinicians face in managing this disease. Recent findings: High-dose corticosteroids with slow tapering and close monitoring are the mainstay of treatment. Investigations into adjunctive treatment have yet to establish other agents as beneficial, but further research is ongoing with some promising results. Summary: GCA represents a challenging illness to clinicians because of its potential for causing blindness and the need for prolonged high doses of corticosteroids with their many complications.
    Current opinion in ophthalmology 09/2015; 26(6). DOI:10.1097/ICU.0000000000000201
  • [Show abstract] [Hide abstract]
    ABSTRACT: Purpose of review: Nonarteritic anterior ischemic optic neuropathy (NAION) is the most common cause of an acute optic neuropathy over the age 50 with an annual incidence of 2-10/100 000. Most patients are left with a permanent decrease in visual acuity and visual field loss. No approved treatment has conclusively reversed the process or prevented a second event that typically involves the previously unaffected eye. Many medical and surgical treatments have been proposed with conflicting results. The goal of this review is to present current data in order to permit clinicians and patients to make an educated decision about treatment. Recent findings: Recently, there has been a flurry of case reports, small clinical trials and testing in animal models of NAION for various treatments for NAION and this review attempts to present the data concisely with the authors' opinions about the reliability of the data. Summary: To date, there is no class I evidence of benefit for the treatment of NAION; however, the aphorism attributed to Carl Sagan, PhD aptly applies: 'Absence of evidence is not evidence of absence'.
    Current opinion in ophthalmology 09/2015; 26(6). DOI:10.1097/ICU.0000000000000199
  • [Show abstract] [Hide abstract]
    ABSTRACT: Purpose of review: IgG4-related disease (IgG4-RD) is a systemic process that can cause significant orbital disease. It can affect both sexes and all ages, with irreversible consequences if left untreated. Diagnosis is currently based upon a combination of clinical and imaging evidence of tissue swelling or mass, serum evidence of elevated IgG4 levels and histopathologic evidence of inappropriate IgG4 presence. The cause of IgG4-RD is as of yet unclear; this lack of understanding and the dearth of prospective studies have limited our ability to manage patients effectively. In this review, we discuss the most recent published evidence regarding best-practice management of IgG4-related orbital disease. Recent findings: Recent literature remains retrospective, and has focused on the use of corticosteroid therapy as a first-line treatment. Rituximab infusions have also received significant attention, among other second-line agents. Radiation therapy has been reported to be effective. Long-term monitoring for relapse, involvement of other organ systems and potential neoplastic transformation is required. Summary: The management of orbital IgG4-RD will gain from more targeted therapy in the future as the underlying cause is better understood. In the meantime, randomized, controlled trials of varying treatment regimens would be of benefit.
    Current opinion in ophthalmology 09/2015; 26(6). DOI:10.1097/ICU.0000000000000204